Skip to content
    KRYS
    Earnings call· Mar 2026(Q1 FY26)

    Krystal Biotech Q1 FY26 earnings call KRYS

    May 4, 2026 Source

    Executive summary

    Krystal Biotech Q1 FY26 — Strong VYJUVEK Growth and Pipeline Advancement

    Krystal Biotech delivered robust Q1 FY26 results, driven by strong global VYJUVEK sales and continued pipeline progress. The company emphasized its financial discipline and the strategic advantage of its FDA platform technology designations, which streamline development. While navigating US market dynamics like insurance changes and patient treatment cadences, Krystal is expanding internationally and advancing multiple registrational studies, positioning for significant catalysts over the next 12-24 months.

    Highlights

    5
    • Global VYJUVEK net revenue reached $116.4 million, representing 9% sequential growth and 32% year-over-year growth.

    • Gross margin remained strong at 95%, slightly up from 94% in Q1 2025.

    • Reported 11th consecutive quarter of positive EPS, with $1.91 per basic share and $1.83 per diluted share.

    • Secured platform technology designations from FDA for KB407 (CF) and KB111 (Hailey-Hailey), in addition to KB801.

    • Completed enrollment for the registrational study of KB803 for corneal abrasions in DDEB patients, with readout expected in Q4 2026.

    Concerns

    3
    • US VYJUVEK revenues were impacted by higher-than-usual insurance switchovers in Q1 2026.

    • The start-stop treatment cadence characteristic of the US patient population shifting towards maintenance regimens creates quarter-to-quarter revenue fluctuations.

    • Pricing negotiations for VYJUVEK remain ongoing in Germany (decision expected H2 2026) and France (decision expected 2027).

    Guidance & targets

    15
    CategoryTargetConfidence
    Germany VYJUVEK pricing decision
    Expected in the second half of 2026
    medium materiality
    Medium
    France VYJUVEK pricing decision
    Expected in 2027
    medium materiality
    Medium
    Italy VYJUVEK launch
    Potential launch in the second half of 2026
    medium materiality
    Medium
    Spain VYJUVEK launch
    Potential opportunity to launch in the second half of the year (2026)
    medium materiality
    Medium
    KB803 registrational study readout
    Readout in the fourth quarter of this year (2026)
    high materiality
    High
    KB801 registrational study readout
    Data readout later this year (2026)
    high materiality
    High
    KB407 open-label study data
    Report data by end of the year (2026)
    medium materiality
    High
    KB407 registrational study design alignment with FDA
    Expected in second half of 2026
    medium materiality
    High
    KB407 registrational study start
    Expected to commence in first half of 2027
    medium materiality
    High
    KB111 HD severity scale development and validation
    Expected to complete in the first half of this year (2026)
    low materiality
    High
    KB111 registrational study design submission to FDA
    Submit in the second half of the year (2026)
    medium materiality
    High
    KB111 registrational study start
    Expected to start in 2027
    medium materiality
    High
    KB408 data update
    Data update later this year (2026)
    medium materiality
    High
    KB707 data update
    Data update at ASCO next month (May 2026)
    medium materiality
    High
    Non-GAAP operating expenses
    $175M to $195M
    high materiality
    High

    Segment performance

    5
    SegmentRevenueYoYQoQMargin
    Global VYJUVEK
    Total global net revenue for VYJUVEK, including sales from commercial launches in Europe and Japan.
    $116.4M32%9%
    United States VYJUVEK
    Revenues impacted by insurance switchovers and start-stop treatment cadence. Strong demand metrics continue.
    Cumulative reimbursement approvals: 695New prescribers in Q1: >60Unique prescribers since launch: >570
    $87.5M
    Europe + Japan VYJUVEK
    Meaningful role in the growth of VYJUVEK over time, with strong word of mouth and increasing engagement.
    DDEB patients prescribed VYJUVEK across Germany, Japan, and France: >140
    $28.9M
    Europe VYJUVEK
    Contribution to international sales, with ongoing pricing negotiations in Germany and France.
    $20.7M
    Japan VYJUVEK
    Contribution to international sales, with specific dynamics like prescription renewal frequency in the first year.
    $8.1M

    Operational metrics

    18
    Cumulative net VYJUVEK revenue
    >$846M
    Since launch

    Cumulative net revenue from VYJUVEK sales since its launch.

    Gross margin
    95%Up from 94% in Q1 2025
    Q1 FY26

    Gross margin for the quarter, benefiting from manufacturing process improvements.

    Cost of goods sold
    $6.3MVs $5M in Q1 2025
    Q1 FY26

    Cost of goods sold for the first quarter.

    R&D expenses
    $15.3MVs $14.3M in Q1 2025
    Q1 FY26

    Driven mainly by payroll, materials, and support costs for production runs across several product candidates.

    G&A expenses
    $41MVs $32.6M in Q1 2025
    Q1 FY26

    Primarily due to increased headcount, compensation, legal consulting, and launch costs for VYJUVEK globally.

    Noncash stock-based compensation
    $13.6MVs $13.5M in Q1 2025
    Q1 FY26

    Included in operating expenses.

    Net income
    $55.9MVs $35.7M in Q1 2025
    Q1 FY26

    Net income for the quarter.

    EPS (basic)
    $1.91Vs $1.24 in Q1 2025
    Q1 FY26

    Basic earnings per share.

    EPS (diluted)
    $1.83Vs $1.20 in Q1 2025
    Q1 FY26

    Diluted earnings per share.

    Cash and investments balance
    >$1B
    Q1 FY26

    Combined cash and investments, positioning the company to support pipeline and global commercial efforts.

    US identified DDEB patients
    ~1200
    Current

    Estimated number of identified DDEB patients in the US. Management hopes to reach 720 patients (60% of 1200) by next quarter. The transcript stated '$720 million number' which is an ASR error for '720 patients'.

    KB803 study enrollment
    16
    Q1 FY26

    Total patients enrolled in the registrational study for KB803.

    KB801 study enrollment target
    60
    Target

    Target enrollment for the KB801 registrational study.

    KB407 open-label study enrollment
    5
    Target

    Number of patients for the open-label single-arm study to evaluate repeat dose safety of KB407 in CF.

    KB111 open-label study enrollment
    7
    Target

    Number of patients for the open-label safety KYANITE-1 study to evaluate KB111 for Hailey-Hailey disease.

    KB803 study powering
    90%
    Study design

    The study is powered to detect at least a 25% reduction in symptom days.

    KB803 affected RD population
    50%
    Current

    KB803 is estimated to affect 50% of the Recessive Dystrophic Epidermolysis Bullosa (RDEB) population.

    KB803 affected dominant population
    10% to 15%
    Current

    KB803 is estimated to affect 10% to 15% of the dominant population.

    Industry KPIs

    1
    MetricValueDetails
    Therapeutic drug market share60%%

    Risks & headwinds

    4
    Higher-than-usual insurance changesQ1 FY26

    Impacted Q1 2026 US VYJUVEK revenues

    Mitigation: Now behind us; company is launching patient support initiatives and educating on label updates for flexibility.

    Start-stop treatment cadenceOngoing

    Impacted US VYJUVEK revenues, making Q-by-Q prediction difficult

    Mitigation: Launching patient support initiatives to integrate VYJUVEK into lifelong routines; focusing on enabling timely access when needed.

    Ongoing pricing negotiations in EuropeH2 FY26 and FY27

    Germany decision expected H2 2026; France decision expected 2027

    Mitigation: Making a compelling value proposition based on clinical benefits; Italy and Spain expected to have definitive reimbursement.

    Country-level fluctuations in international launchQuarter-to-quarter

    Not quantified, but acknowledged for individual markets like Japan's prescription renewal frequency

    Mitigation: Mitigated by diversification that geographic expansion brings; overall global trajectory is positive.

    What to watch in Q2 FY26

    5

    Germany VYJUVEK pricing decision

    H2 FY26
    CurrentNegotiations ongoing
    TargetDecision expected

    Why it matters

    This decision will set a key benchmark for VYJUVEK's pricing and reimbursement in a major European market, impacting future international revenue.

    In Germany and France, pricing negotiations remain ongoing. We continue to expect a decision in Germany in the second half of 2026.

    Q&A highlights

    7

    How should we think about US growth for the rest of 2026 and the continuation of strong ex-US trends? Also, what are the endpoints for CF 24-week data and the decision process for the pivotal study?

    Management expects overall positive US growth despite Q-by-Q fluctuations due to start-stop treatment. Ex-US growth is strong and expected to continue. For CF, the 24-week study focuses on repeat dose safety, with FEV1 and PRO scales as exploratory endpoints. The registrational trial design is being finalized with FDA and CFF, aiming for an innovative approach.

    I know we've previously said there's maybe about 1,200 identified patients and we're steadily marching towards that and even hope to get to that $720 million number by next quarter, right? So we're at 60% market share.

    asked by Jiale Song · answered by Krish Krishnan

    2 min read6 chapters

    Detailed Narrative

    01

    Company Overview and Strategic Positioning

    Krystal Biotech celebrates its 10th anniversary, highlighting its transformation into a durable, fully integrated company with financial strength. The company has not accessed capital markets since 2022, maintaining a strong balance sheet and generating meaningful operating leverage. Management believes the next 12-24 months will be one of the most exciting periods, with four registrational readouts expected this year and next, underscoring a disciplined approach to growth and value creation.

    02

    Platform Technology Designations and Pipeline Advantage

    The FDA has granted platform technology designations to KB407 (Cystic Fibrosis) and KB111 (Hailey-Hailey), adding to the prior designation for KB801. These designations streamline interactions with the agency and development plans, reducing risk, cost, and time for future programs. This unique advantage allows each pipeline milestone to strengthen the collective regulatory data set, creating a compounding benefit for Krystal's development efforts.

    03

    International VYJUVEK Launch Dynamics

    The international launch of VYJUVEK is progressing well, with Europe and Japan contributing $28.9 million in net revenue. The company is focused on deepening penetration in current markets (Germany, France, Japan), securing positive access and reimbursement, and expanding into additional major European markets like Italy and Spain in H2 2026. Physicians in these markets are already aware of VYJUVEK's benefits from its US launch, aiding education, though pricing negotiations remain a key factor.

    04

    US VYJUVEK Launch and Patient Support

    In the US, VYJUVEK has secured over 695 reimbursement approvals, with over 60 new prescribers in Q1 and 570 unique prescribers since launch. While Q1 revenues were impacted by insurance switchovers and the natural start-stop treatment cadence, the company is focused on establishing long-term relationships with patients. Recent label updates providing administration flexibility (self-administration or nurse support) are valuable, and patient support initiatives are educating on these updates to integrate VYJUVEK into lifelong routines.

    05

    Ophthalmology Pipeline Progress (KB803 & KB801)

    Krystal is advancing two ophthalmology registrational studies. Enrollment for KB803, for corneal abrasions in DDEB patients, is complete with 16 patients, and a readout is expected in Q4 2026. The IOLITE study is a randomized, intrapatient double-blind, decentralized placebo-controlled study with a crossover design. KB801 for neurotropic keratitis is also progressing, with a target enrollment of 60 patients and a data readout expected later in 2026.

    06

    Broader Pipeline and Clinical Readouts

    The broader pipeline includes initiation of open-label studies for repeat dose KB407 (CF) and KB111 (Hailey-Hailey), both expected to read out later in 2026. KB407's registrational study design is being developed collaboratively with the FDA and CFF, with an innovative approach potentially including natural history data. KB111's HD severity scale validation is nearing completion, and a registrational study is planned for 2027. KB408 (AATD lung disease) and KB707 (NSCLC) are also advancing, with data updates expected this year, including KB707 at ASCO next month.

    AI-generated summary of the company’s earnings call. Not investment advice.